Immunotherapies may never be the same.

Leveraging the Power of the Natural Human Immune System

SAB Biotherapeutics is a clinical-stage biopharmaceutical company with a unique approach to immunotherapies –unleashing the power of the body’s natural defense system to address the complexity, emergence and mutation of human disease.

The body’s natural defense system produces polyclonal antibodies against invaders such as viruses, allergens, bacteria, toxins, and other pathogens. We’ve harnessed the natural power of the human immune response in a therapeutic engine, the DiversitAb™ platform, to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies without the need for human donors.

Made possible by the sophistication of science and genius of nature, SAB’s innovative DiversitAb™ platform enables a scalable and reliable production of highly-potent polyclonal antibody therapies with the potential to address the emergence, mutation, and diversity of modern health challenges including COVID-19, seasonal influenza, Type 1 diabetes, and cancers.

Advancing a New Class of Immunotherapies

We are dedicated to advancing this new class of immunotherapies, leveraging the native human immune response, with significant potential across broad therapeutic categories including infectious disease immune system disorders and immuno-oncology.

Our team of scientists, researchers and professionals has made it their life's work–with technology and tenacity–to pioneer a powerful new platform to make an impact on human health that’s both personal + global.

Advanced engineering and a refined suite of technologies optimized over nearly two decades

Asset 1